About AngelMed

AMSG3 Implantable DeviceAngel Medical Systems is an innovator in today’s cardiac medical device arena. The company has developed the AngelMed Guardian system, which is designed to detect and warn patients of acute episodes of cardiac ischemia related to the progression of coronary artery disease and thrombotic coronary occlusion caused by vulnerable plaque ruptures.

Having completed both US and OUS clinical trials, the company has recently enrolled over 900 patients for its ALERTS Phase II US Pivotal Study. Commercially available in Brazil, this leading-edge cardiac device has been developed to reduce time to treatment, minimize heart muscle damage, and improve patient outcomes. In 2010, AngelMed received CE market approval for the commercial sale of the AngelMed Guardian System in Europe.

alt

For its groundbreaking work, AngelMed has received several honors.

Best Places


Mar 2013
"Best Places to Work in New Jersey" - benefiting New Jersey's economy, workforce, and businesses.

Best Places


Apr 2012
"Best Places to Work in New Jersey" - benefiting New Jersey's economy, workforce, and businesses.

Best Places


Apr 2011
"Best Places to Work in New Jersey" - benefiting New Jersey's economy, workforce, and businesses.

MDEA Award

Jun 2010
"2010 Medical Design Excellence Awards (MDEA)" - recognizing the achievements of medical product companies.

Best Places


Apr 2010
"Best Places to Work in New Jersey" - benefiting New Jersey's economy, workforce, and businesses.

NJTC

Nov 2008
“New Jersey Company to Watch” - recognized as an up and coming company with exciting new technologies poised to make an impact on the medical community.